Design and synthesis of pyridazin‐4‐one derivatives as necroptosis inhibitors
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.202400594 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Yuxiang An und 10 weiteren Autor:innen. Beteiligte Einrichtung: Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China. Hauptthemen laut MEDLINE: Necroptosis, Drug Design, Receptor-Interacting Protein Serine-Threonine Kinases, Pyridazines. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Key R&D Program "Strategic Scientific and Technological Innovation Cooperation" Key Project, Natural Science Foundation of China for Innovation Research Group, Foundation of Shanghai Science and Technology Committee.
Abstract (Originalsprache)
Necroptosis is a regulated inflammatory cell death process that is closely associated with autoimmune diseases, acute ischemic injuries, neurodegenerative disorders, and so on. Due to the crucial role of receptor‐interacting protein kinase 1 (RIPK1) in the necroptosis pathway, RIPK1 inhibitors are believed to have great potential in the treatment of necroptosis‐related diseases. In this article, we reported a series of pyridazin‐4‐one derivatives as potent necroptosis inhibitors for both human and mouse cells. The representative compound 13 exhibited favorable RIPK1 selectivity and dose‐dependently inhibited RIPK1 phosphorylation. The in vivo pharmacokinetic study indicated that compound 13 was an orally available candidate. Finally, molecular docking and molecular dynamics simulations were performed to elucidate the binding pattern of compound 13 with RIPK1. Collectively, compound 13 represents a promising lead compound for the future development of RIPK1‐targeted necroptosis inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
- School of Pharmacy, University of Chinese Academy of Sciences, Beijing, China.
- Cancer Research Center, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
- School of Life Sciences and Technology, ShanghaiTech University, Shanghai, China.
- State Key Laboratory of Natural Medicines, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, People's Republic of China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Förderung
- National Key R&D Program "Strategic Scientific and Technological Innovation Cooperation" Key Project
- Natural Science Foundation of China for Innovation Research Group
- Foundation of Shanghai Science and Technology Committee
- Shandong Laboratory Program
Zitieren
APA
An, Y., Peng, X., Wang, T., Liu, K., Feng, D., Fang, C., Zhou, X., Geng, M., Duan, W., Ai, J., & Zhang, H. (2025). Design and synthesis of pyridazin‐4‐one derivatives as necroptosis inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400594
Vancouver
An Y, Peng X, Wang T, Liu K, Feng D, Fang C, et al. Design and synthesis of pyridazin‐4‐one derivatives as necroptosis inhibitors. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400594
BibTeX
@article{An2025,
author = {An, Yuxiang and Peng, Xia and Wang, Tianchen and Liu, Kaiyuan and Feng, Dazhi and Fang, Chen and Zhou, Xuan and Geng, Meiyu and Duan, Wenhu and Ai, Jing and Zhang, Hefeng},
title = {Design and synthesis of pyridazin‐4‐one derivatives as necroptosis inhibitors},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.202400594}
}
EUVIMED